Iranian
Biomedical Journal
Volume 30, Issue 1 (1-2026)
IBJ 2026, 30(1): 47-58 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nejat L, Hatami M, Adelipour M, Igder S, Rashidi M. Quercetin and 5-Fluorouracil Synergistically Suppress ZEB1 and Restore Epithelial Integrity in Triple-Negative Breast Cancer. IBJ 2026; 30 (1) :47-58
URL: http://ibj.pasteur.ac.ir/article-1-5156-en.html
URL: http://ibj.pasteur.ac.ir/article-1-5156-en.html
Abstract:
Background: Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its metastatic features and resistance to conventional therapies. This study investigated the synergistic potential of quercetin (QC), a natural flavonoid, and 5-fluorouracil (5-FU) in targeting epithelial-mesenchymal transition (EMT) to inhibit proliferation and migration of the MDA-MB-231 TNBC cell line.
Methods: Cytotoxicity and selectivity were assessed using the MTT assay in MDA-MB-231 cells and normal MRC-5 fibroblasts. Synergy was quantified using combination index (CI) values. Scratch assay was assessed for migration inhibition, while quantitative RT-PCR analyzed EMT-related gene expression (Vimentin, ZEB1, N-cadherin, and E-cadherin). Western blotting confirmed protein expression of ZEB1 and E-cadherin following treatment with QC (50 μM), 5-FU (25 nM), or their combination.
Results: QC and 5-FU demonstrated concentration- and time-dependent cytotoxicity in MDA-MB-231 cells, with QC being highly selective for cancer cells. Toxicity in normal MRC-5 fibroblasts occurred only at 800 µM (25% viability). The combination of 50 µM of QC and 25 nM of 5-FU exhibited the strongest synergy (CI = 0.08), reducing viability by 75% and migration by 87.8%. QC alone downregulated ZEB1, Vimentin, and N-cadherin, while
5-FU further reduced these markers. Combined treatment enhanced suppression (ZEB1: 0.46-fold; Vimentin: 0.47-fold; N-cadherin: 0.68-fold) and significantly upregulated E-cadherin (3.75-fold), indicating EMT reversal. Western blotting confirmed decreased ZEB1 and increased E-cadherin by over four-fold with QC + 5-FU, indicating a shift to an epithelial phenotype.
Conclusions: Combining QC and 5-FU effectively inhibited TNBC proliferation and migration while minimizing toxicity to normal cells. This dual-action strategy offers a promising low-toxicity therapeutic approach for aggressive TNBC.
Methods: Cytotoxicity and selectivity were assessed using the MTT assay in MDA-MB-231 cells and normal MRC-5 fibroblasts. Synergy was quantified using combination index (CI) values. Scratch assay was assessed for migration inhibition, while quantitative RT-PCR analyzed EMT-related gene expression (Vimentin, ZEB1, N-cadherin, and E-cadherin). Western blotting confirmed protein expression of ZEB1 and E-cadherin following treatment with QC (50 μM), 5-FU (25 nM), or their combination.
Results: QC and 5-FU demonstrated concentration- and time-dependent cytotoxicity in MDA-MB-231 cells, with QC being highly selective for cancer cells. Toxicity in normal MRC-5 fibroblasts occurred only at 800 µM (25% viability). The combination of 50 µM of QC and 25 nM of 5-FU exhibited the strongest synergy (CI = 0.08), reducing viability by 75% and migration by 87.8%. QC alone downregulated ZEB1, Vimentin, and N-cadherin, while
5-FU further reduced these markers. Combined treatment enhanced suppression (ZEB1: 0.46-fold; Vimentin: 0.47-fold; N-cadherin: 0.68-fold) and significantly upregulated E-cadherin (3.75-fold), indicating EMT reversal. Western blotting confirmed decreased ZEB1 and increased E-cadherin by over four-fold with QC + 5-FU, indicating a shift to an epithelial phenotype.
Conclusions: Combining QC and 5-FU effectively inhibited TNBC proliferation and migration while minimizing toxicity to normal cells. This dual-action strategy offers a promising low-toxicity therapeutic approach for aggressive TNBC.
Keywords: Fluorouracil, Epithelial-mesenchymal transition, Quercetin, Triple negative breast neoplasms, Zinc finger E-box binding homeobox
Type of Study: Full Length/Original Article |
Subject:
Cancer Biology
References
1. Sedeta E, Sung H, Laversanne M, Bray F, Jemal A. Recent mortality patterns and time trends for the major cancers in 47 countries worldwide. Cancer Epidemiol Biomarkers Prev. 2023;32(7):894-905. [DOI:10.1158/1055-9965.EPI-22-1133]
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. [DOI:10.3322/caac.21763]
3. Chapdelaine AG, Sun G. Challenges and opportunities in developing targeted therapies for triple negative breast cancer. Biomolecules. 2023;13(8):1207. [DOI:10.3390/biom13081207]
4. Xia YT, Zhang YQ, Chen L, Min L, Huang D, Zhang Y, et al. Suppression of migration and invasion by taraxerol in the triple-negative breast cancer cell line MDA-MB-231 via the ERK/Slug axis. Plos One. 2023;18(9):291693. [DOI:10.1371/journal.pone.0291693]
5. Goncharov AP, Vashakidze N, Kharaishvili G. Epithelial-mesenchymal transition: A fundamental cellular and microenvironmental process in benign and malignant prostate pathologies. Biomedicines. 2024;12(2):418. [DOI:10.3390/biomedicines12020418]
6. Youssef KK, Nieto MA. Epithelial-mesenchymal transition in tissue repair and degeneration. Nat Rev Mol Cell Biol. 2024;25(9):720-39. [DOI:10.1038/s41580-024-00733-z]
7. Saha M, Ghosh SS. Engineered hybrid nanosystem for homologous targeting of EMT induced triple negative breast cancer cells. ACS Appl Bio Mater. 2023;6(2):681-93. [DOI:10.1021/acsabm.2c00925]
8. Perez-Oquendo M. Regulation and function of ZEB1 acetylation in lung adenocarcinoma progression and metastasis. Mol Cancer Ther. 2023;5:20-23.
9. Jiang Y, Zhao M, Tang W, Zheng X. Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: A systematic review and network meta-analysis. BMC Cancer. 2024;24(1):188. [DOI:10.1186/s12885-024-11937-z]
10. Lopez-Gonzalez L, Sanchez Cendra A, Sanchez Cendra C, Roberts Cervantes ED, Espinosa JC, Pekarek T, et al. Exploring biomarkers in breast cancer: Hallmarks of diagnosis, treatment, and follow-up in clinical practice. Medicina. 2024;60(1):168. [DOI:10.3390/medicina60010168]
11. Asnaashari S, Amjad E, Sokouti B. Synergistic effects of flavonoids and paclitaxel in cancer treatment: A systematic review. Cancer Cell Int. 2023;23(1):211. [DOI:10.1186/s12935-023-03052-z]
12. Khazaei M, Bozorgi M, Khazaei M, Khazaei F, Rashidi Z. Quercetin and raloxifene effect on breast cancer cell viability, migration, nitric oxide secretion and apoptotic genes expression. WCRJ. 2023;10:2679.
13. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47. [DOI:10.1186/2050-6511-15-47]
14. Asadizade S, Hatami M, Bavarsad SS, Kabizade B, Shakerian E, Rashidi M. Curcumin modulates NOX gene expression and ROS production via P-Smad3C in TGF-β-activated hepatic stellate cells. Iran Biomed J. 2024;28(1):31-7. [DOI:10.61186/ibj.4005]
15. Sharma V, Chaudhary AA, Bawari S, Gupta S, Mishra R, Khan S-U-D, et al. Unraveling cancer progression pathways and phytochemical therapeutic strategies for its management. Front Pharmacol. 2024;15:1414790. [DOI:10.3389/fphar.2024.1414790]
16. Chen Q, Guo H, Jiang H, Hu Z, Yang X, Yuan Z, et al. S100A2 induces epithelial-mesenchymal transition and metastasis in pancreatic cancer by coordinating transforming growth factor β signaling in SMAD4-dependent manner. Cell Death Discov. 2023;9(1):356. [DOI:10.1038/s41420-023-01661-1]
17. Aslani F, Afarin R, Madiseh ND, Nasab HB, Monjezi S, Igder S, et al. Potentiation of apoptotic effect of combination of etoposide and quercetin on HepG2 liver cancer cells. Hepat Mon. 2023;23(1):136194. [DOI:10.5812/hepatmon-136194]
18. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research. 2010;70(2):440-6. [DOI:10.1158/0008-5472.CAN-09-1947]
19. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI:10.3322/caac.21660]
20. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178-96. [DOI:10.1038/nrm3758]
21. Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: A historical overview. Transl Oncol. 2020;13(6):100773. [DOI:10.1016/j.tranon.2020.100773]
22. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1-2):15-33. [DOI:10.1007/s10555-008-9169-0]
23. Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128-34. [DOI:10.1038/nrc.2017.118]
24. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-54. [DOI:10.1038/nrc822]
25. Silva C, Caramelo O, Almeida-Santos T, Ribeiro Rama AC. Factors associated with ovarian function recovery after chemotherapy for breast cancer: A systematic review and meta-analysis. Hum Reprod. 2016;31(12):2737-49. [DOI:10.1093/humrep/dew224]
26. Rauf A, Imran M, Khan IA, Ur‐Rehman M, Gilani SA, Mehmood Z, et al. Anticancer potential of quercetin: A comprehensive review. Phytother Res. 2018;32(11):2109-30. [DOI:10.1002/ptr.6155]
27. Roshanazadeh M, Rezaei HB, Rashidi M. Quercetin synergistically potentiates the anti-metastatic effect of 5-fluorouracil on the MDA-MB-231 breast cancer cell line. Iran J Basic Med Sci. 2021;24(7):928-34.
28. Lei M, Zhou Q, Chen A, Zheng W, Li W. Effect and significance of quercetin on the expression of CD44v6 and E-cadherin in hela cells. Int J Front Med. 2023;5(10):53-6. [DOI:10.25236/IJFM.2023.051009]
29. Mawalizadeh F, Mohammadzadeh G, Khedri A, Rashidi M. Quercetin potentiates the chemosensitivity of MCF-7 breast cancer cells to 5-fluorouracil. Mol Biol Rep. 2021;48(12):7733-42. [DOI:10.1007/s11033-021-06782-3]
30. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008;7(4):12. [DOI:10.1186/jbiol69]
31. Matsumoto H, Okumura H, Murakami H, Kubota H, Higashida M, Tsuruta A, et al. Fluctuation in plasma 5-fluorouracil concentration during continuous 5-fluorouracil infusion for colorectal cancer. Anticancer Res. 2015;35(11):6193-9.
32. Abe Y, Sakuyama N, Sato T, Kishine K, Nagayasu K, Nakatani A, et al. Evaluation of the 5‑fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy. Mol Clin Oncol. 2019;11(3):289-95. [DOI:10.3892/mco.2019.1893]
33. Srivastava S, Somasagara RR, Hegde M, Nishana M, Tadi SK, Srivastava M, et al. Quercetin, a natural flavonoid interacts with DNA, arrests cell cycle and causes tumor regression by activating mitochondrial pathway of apoptosis. Sci Rep. 2016;6(1):24049. [DOI:10.1038/srep24049]
34. Lu J, Wang Z, Li S, Xin Q, Yuan M, Li H, et al. Quercetin inhibits the migration and invasion of HCCLM3 cells by suppressing the expression of p-Akt1, matrix metalloproteinase (MMP) MMP-2, and MMP-9. Med Sci Monit. 2018;24:2583-9. [DOI:10.12659/MSM.906172]
35. Hatami M, Kouchak M, Kheirollah A, Khorsandi L, Rashidi M. Effective inhibition of breast cancer stem cell properties by quercetin-loaded solid lipid nanoparticles via reduction of Smad2/Smad3 phosphorylation and β-catenin signaling pathway in triple-negative breast cancer. Biochem Biophys Res Commun. 2023;664:69-76. [DOI:10.1016/j.bbrc.2023.03.077]
36. Wu C, Shi W, Zhang S. ZEB1 promotes DNA homologous recombination repair and contributes to the 5-fluorouracil resistance in colorectal cancer. Am J Cancer Res. 2023;13(9):4101-14.
37. Wang D, Du G, Chen X, Wang J, Liu K, Zhao H, et al. Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer. Cell Death Differ. 2024;31(6):779-91. [DOI:10.1038/s41418-024-01295-5]
38. Ban Y, Zou Y, Liu Y, Lee S, Bednarczyk RB, Sheng J, et al. Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer. Elife 2024;12:89486. [DOI:10.7554/eLife.89486.3]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |